BillionToOne, Inc. vs RadNet, Inc., two Medical Diagnostics stocks. A side-by-side on valuation, growth, margins, returns, and what each price is betting.
Where BLLN and RDNT diverge most: on operating margin, BLLN reads 16.4% and RDNT reads -4.2%; on net margin, BLLN reads 1.7% and RDNT reads -0.7%. The rest of the comparable metrics sit closer together. The bull and bear cases for each are in their full reports below.
| Metric | BLLN | RDNT |
|---|---|---|
| Price | $138.56 | $63.83 |
| Market cap | $7.3B | $5.0B |
| Sector | Medical Diagnostics | Medical Diagnostics |
| Stage | Growth | Growth |
| P/B | 14.53 | 3.71 |
| P/S | 25.40 | 2.34 |
| EV/EBITDA | 429.9 | 25.4 |
| Revenue growth | +100.6% | +14.7% |
| Gross margin | 73.0% | — |
| Operating margin | 16.4% | -4.2% |
| Net margin | 1.7% | -0.7% |
| Return on equity | 0.9% | -1.1% |
| Return on assets | 0.7% | -0.4% |
| Return on invested capital | 2.0% | 2.0% |
| FCF yield | 0.4% | 6.7% |
| Debt / equity | 0.18 | 0.82 |
| Current ratio | 10.92 | 1.17 |
| Altman Z (solvency) | 6.95 | 1.71 |
| Piotroski F (quality) | 5 / 9 | 5 / 9 |
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
The stronger value is highlighted per metric where one is strictly better on that single number; it is not an overall verdict on either company. For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.